Developer docs
API playgroundTry for free, no card

Search company profiles

Diagnos Inc.

Full company profile

uuid005o6wa

Namestring
Diagnos Inc.
Legal namestring
DIAGNOS Inc.
Company typeenum
Public
Founded yearint
2008
Operating statusenum
Operating
Ownership categoryenum
akta.pro rankint
HeadquartersBrossard, Canada
HQ citystring
Brossard
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
retinal image analysis, AI medical diagnostics, diabetic retinopathy screening, ophthalmology AI platform, medical imaging software
Industry3 codes
PRIMARYHDAAAEAH
Medical Imaging AI
SECONDARYHLAHAJAB
Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAFAKAI
Vision & Ophthalmic Diagnostic Centers (Optometry/OCT/Retinal Imaging)
NAICS code2 codes
  • Offices of Optometrists621320
  • Optical Goods Retailers45613
SIC code2 codes
  • Optical Instruments & Lenses3827
  • Laboratory Analytical Instruments3826
Product category
AI Medical Imaging Software
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1AI Medical Analysis Services
TypeSubscription Recurring
Description

DIAGNOS generates revenue through licensing its AI-powered retinal analysis platform (CARA System) to healthcare providers, hospitals, and clinics. Revenue is derived from multi-year contracts with healthcare networks and per-analysis fees.

diagnosmedical.com
2Technology Licensing
TypeLicensing Royalties
Description

Licensing of proprietary AI algorithms and cloud-based medical analysis technology to partners including Essilor International and exclusive distribution partners in DACH/Europe regions.

diagnosmedical.com
3Professional Services
TypeProfessional Services
Description

Implementation, training, and technical support services for healthcare facility deployment of AI screening solutions.

diagnosmedical.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Infrastructure, Operations
Pricing details1 tier
1Enterprise licensing through multi-year contracts with healthcare providers
ModelSubscriptionBilling cadenceMulti-year contract
Notes

Pricing appears to be negotiated on a per-contract basis through enterprise sales. No public pricing tiers available.

diagnosmedical.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 4 records shown
1CARA
Description

AI-assisted screening platform for diabetic retinopathy and other ocular conditions.

diagnosmedical.com
+3 more records
Core offering1 text field

DIAGNOS develops and commercializes AI-powered retinal image analysis software (centered on its CARA System) for the early detection of diabetic retinopathy and other ocular diseases. The platform combines proprietary deep learning algorithms trained on 500,000+ retinal images with a real-time cloud-based analysis infrastructure, deployed to hospitals, eye clinics, optical retailers, and medical tourism operators under multi-year licensing and subscription contracts.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 500,000+ retinal images analyzed
+3 more records
Product overview1 text field

DIAGNOS offers a unified AI-powered medical device platform centered on its CARA System for retinal image analysis and early disease detection. The core offering consists of the CARA System (FDA/SFDA/Health Canada-cleared) working alongside the RetinaCare automated analysis module and the FLAIRE platform for AI-assisted medical diagnosis. The portfolio also includes a real-time cloud analysis platform and CARA STROKE (stroke risk assessment via retinal analysis). Together, these products enable AI-assisted early detection of ocular diseases and systemic health conditions through intelligent retinal imaging analysis.

Product and service4 records
1CARA System
CategoryAI retinal image analysis software
Description

DIAGNOS' primary AI-powered medical device platform for retinal image analysis. The CARA System enables early detection of ocular diseases including diabetic retinopathy and supports clinical decision-making through automated analysis of retinal images with real-time cloud processing. Cleared by Health Canada and the Saudi FDA, and used by hospitals, eye clinics, optical retailers, and medical tourism operators under multi-year contracts.

2FLAIRE Platform
CategoryAI medical diagnosis software
Description

AI-based medical diagnosis platform referenced as DIAGNOS' broader AI technology for applying artificial intelligence to medical diagnosis beyond retinal screening. Used in support of the company's clinical AI portfolio.

3CARA STROKE
CategoryAI cardiovascular risk screening software
Description

Application extending DIAGNOS' retinal AI capabilities beyond ophthalmology to stroke and cardiovascular risk assessment through analysis of retinal images.

4Real-time Cloud Medical Analysis Platform
CategoryCloud-based medical image analysis infrastructure
Description

Cloud-based platform enabling immediate, real-time processing and analysis of medical images with secure data handling, supporting the deployment of CARA System analysis at equipped healthcare centers.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic academic partnership with leading Montreal engineering school. Dr. Ismail Ben Ayed holds the AI in Medical Imaging Research Chair at ÉTS. Joint research and over $1 million federal funding announcement for next-generation retinal AI development. Collaboration involves training algorithms on millions of images from hospital and academic center partnerships.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Regional Quebec health network where DIAGNOS deployed its AI-assisted diabetic retinopathy screening across the healthcare network. Featured in Radio-Canada/ICI Gaspésie media coverage as a major deployment of AI screening technology in public healthcare.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Memorandum of understanding signed for potential collaboration with global optical lens leader. Represents strategic positioning for international expansion through major optical industry player.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Exclusive distribution agreement for DACH countries (Germany, Austria, Switzerland) and broader Europe, enabling access to significant European healthcare market through established distribution channels.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Multi-year agreement with major Canadian optical retail chain to integrate DIAGNOS AI technology across IRIS/New Look Vision retail locations, transforming optical retail into preventive screening hubs.

6Opticalia (Spain)
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Pilot program in Spain testing DIAGNOS AI-powered eye screening technology with European optical retailer for potential broader deployment.

diagnosmedical.com
7Cielo Vista Eye Clinic (Mexico)
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

3-year contract with Mexican eye clinic for deployment of AI-powered retinal analysis services, representing established presence in Latin American market.

diagnosmedical.com
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

3-year contract with California medical group for AI screening services deployment, representing U.S. market presence in healthcare screening.

9Juarez Health Medical Tourism Cluster
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Multi-year contract with medical tourism cluster for AI-assisted healthcare screening services targeting international patients.

diagnosmedical.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

3-year contract renewal with existing strategic partner for continued collaboration on AI-powered diagnostic solutions.

11Colombia Telemedecine Centre
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Service agreement with Colombian telemedicine organization for deployment of DIAGNOS screening technology in Latin America.

diagnosmedical.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Official opening of AI-assisted screening clinic at Magrabi Hospital, establishing presence in Middle East healthcare market.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Eyenuk's EyeArt AI system is an FDA-cleared autonomous diabetic retinopathy screening platform sold to primary care and optometry networks. Directly comparable to DIAGNOS' CARA in target use case (diabetic retinopathy screening) and customer base (eye care clinics, primary care).

TypeBroad incumbent
Description

Optos, owned by Nikon, provides ultra-widefield retinal imaging devices (optomap) used in diabetic retinopathy screening and ocular disease detection. Sells imaging hardware and integrated screening solutions across the same customer segments as DIAGNOS.

TypeDirect peer
Description

AEYE Health provides FDA-cleared AI-based retinal screening for diabetic retinopathy with a single-image-per-eye workflow. Direct peer to DIAGNOS in autonomous AI screening sold to primary care and optometry channels.

TypeBroad incumbent
Description

Topcon is a major ophthalmic imaging and healthcare technology company whose Harmony/Imagenet clinical data platforms integrate with AI screening. Broader portfolio than DIAGNOS but operates in the same retinal imaging and screening ecosystem.

5Carl Zeiss Meditec (ZEISS Medical Technology)
TypeBroad incumbent
Description

ZEISS Meditec is a major ophthalmic device and diagnostics company with CIRRUS OCT and integrated screening workflows. Broad incumbent in retinal imaging that DIAGNOS integrates with and competes against for clinical workflow budget.

TypeDirect peer
Description

Digital Diagnostics developed IDx-DR, the first FDA-cleared autonomous AI for diabetic retinopathy detection. Direct competitor to DIAGNOS in AI retinal screening for primary care and eye care settings, with similar clinical validation and regulatory positioning.

TypeEmerging player
Description

RetinaLyze offers cloud-based AI screening for diabetic retinopathy and other retinal conditions, primarily serving European primary care and optometry. Overlaps with DIAGNOS in AI retinal screening use case, though at smaller commercial scale.

TypeBroad incumbent
Description

Heidelberg Engineering is a global leader in OCT, confocal microscopy, and retinal imaging hardware used in ophthalmology. Provides the imaging devices DIAGNOS often integrates with and competes indirectly via their own AI workflows (Heidelberg AppWay).

TypeEmerging player
Description

Verily (an Alphabet company) has developed AI-driven retinal screening for diabetic retinopathy and cardiovascular risk assessment. A platform-scale emerging player whose capabilities overlap directly with DIAGNOS' CARA and CARA STROKE roadmaps.

TypeDirect peer
Description

RetinAI Discovery is an AI platform for retinal image analysis and ophthalmology data management used in clinical research and screening workflows. Comparable to DIAGNOS in retinal AI analytics and clinical/research deployments.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Diagnos Inc.

AI Medical Imaging Softwarediagnosmedical.com

Diagnos Inc. firmographics

Firmographics
Name
Diagnos Inc.
Legal name
DIAGNOS Inc.
Website
https://diagnosmedical.com
Company type
Public
Founded year
2008
Operating status
Operating
Ownership category
akta.pro rank

Diagnos Inc. industry classification

Industry
Product category
AI Medical Imaging Software
NAICS
Offices of Optometrists (621320), Optical Goods Retailers (45613)
SIC
Optical Instruments & Lenses (3827), Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHDAAAEAH
Medical Imaging AI
SECONDARYHLAHAJAB
Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAFAKAI
Vision & Ophthalmic Diagnostic Centers (Optometry/OCT/Retinal Imaging)

Keywords

  • Retinal image analysis
  • AI medical diagnostics
  • Diabetic retinopathy screening
  • Ophthalmology AI platform
  • Medical imaging software

Where Diagnos Inc. is headquartered

Location

Headquarters

HQ city
Brossard
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

Diagnos Inc. business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Infrastructure, Operations

Revenue model

  1. AI Medical Analysis Services: DIAGNOS generates revenue through licensing its AI-powered retinal analysis platform (CARA System) to healthcare providers, hospitals, and clinics. Revenue is derived from multi-year contracts with healthcare networks and per-analysis fees.
  2. Technology Licensing: Licensing of proprietary AI algorithms and cloud-based medical analysis technology to partners including Essilor International and exclusive distribution partners in DACH/Europe regions.
  3. Professional Services: Implementation, training, and technical support services for healthcare facility deployment of AI screening solutions.

Pricing tiers

ModelBillingPrice
SubscriptionMulti-year contractEnterprise licensing through multi-year contracts with healthcare providers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Diagnos Inc. product offering

Product offering

Core offering

DIAGNOS develops and commercializes AI-powered retinal image analysis software (centered on its CARA System) for the early detection of diabetic retinopathy and other ocular diseases. The platform combines proprietary deep learning algorithms trained on 500,000+ retinal images with a real-time cloud-based analysis infrastructure, deployed to hospitals, eye clinics, optical retailers, and medical tourism operators under multi-year licensing and subscription contracts.

Product overview

DIAGNOS offers a unified AI-powered medical device platform centered on its CARA System for retinal image analysis and early disease detection. The core offering consists of the CARA System (FDA/SFDA/Health Canada-cleared) working alongside the RetinaCare automated analysis module and the FLAIRE platform for AI-assisted medical diagnosis. The portfolio also includes a real-time cloud analysis platform and CARA STROKE (stroke risk assessment via retinal analysis). Together, these products enable AI-assisted early detection of ocular diseases and systemic health conditions through intelligent retinal imaging analysis.

Differentiator

Problem solved

Functional benefit

Brands

  • CARA: AI-assisted screening platform for diabetic retinopathy and other ocular conditions.
  • RetinaCare
  • FLAIRE
  • CARA STROKE

Products and services

  • CARA System DIAGNOS' primary AI-powered medical device platform for retinal image analysis. The CARA System enables early detection of ocular diseases including diabetic retinopathy and supports clinical decision-making through automated analysis of retinal images with real-time cloud processing. Cleared by Health Canada and the Saudi FDA, and used by hospitals, eye clinics, optical retailers, and medical tourism operators under multi-year contracts.
  • FLAIRE Platform AI-based medical diagnosis platform referenced as DIAGNOS' broader AI technology for applying artificial intelligence to medical diagnosis beyond retinal screening. Used in support of the company's clinical AI portfolio.
  • CARA STROKE Application extending DIAGNOS' retinal AI capabilities beyond ophthalmology to stroke and cardiovascular risk assessment through analysis of retinal images.
  • Real-time Cloud Medical Analysis Platform Cloud-based platform enabling immediate, real-time processing and analysis of medical images with secure data handling, supporting the deployment of CARA System analysis at equipped healthcare centers.

Quantifiable outcome

  • 500,000+ retinal images analyzed
  • +3 more outcomes

Companies that use Diagnos Inc.

Customer profile

Named customers8 records

Segments4 records

Ideal customer profiles4 records

Diagnos Inc. technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature6 records

Diagnos Inc. partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered core, flagship and minor.

  • ÉTS Montreal (École de technologie supérieure)coreStrategic or Co-development PartnerStrategic academic partnership with leading Montreal engineering school. Dr. Ismail Ben Ayed holds the AI in Medical Imaging Research Chair at ÉTS. Joint research and over $1 million federal funding announcement for next-generation retinal AI development. Collaboration involves training algorithms on millions of images from hospital and academic center partnerships.
  • CISSS de la GaspésieflagshipStrategic or Co-development PartnerRegional Quebec health network where DIAGNOS deployed its AI-assisted diabetic retinopathy screening across the healthcare network. Featured in Radio-Canada/ICI Gaspésie media coverage as a major deployment of AI screening technology in public healthcare.
  • Essilor InternationalcoreStrategic or Co-development PartnerMemorandum of understanding signed for potential collaboration with global optical lens leader. Represents strategic positioning for international expansion through major optical industry player.
  • Exclusive DACH/Europe Distribution PartnercoreChannel Partner/ Reseller/ DistributorExclusive distribution agreement for DACH countries (Germany, Austria, Switzerland) and broader Europe, enabling access to significant European healthcare market through established distribution channels.
  • IRIS / New Look Vision Group Inc.coreChannel Partner/ Reseller/ DistributorMulti-year agreement with major Canadian optical retail chain to integrate DIAGNOS AI technology across IRIS/New Look Vision retail locations, transforming optical retail into preventive screening hubs.
  • Opticalia (Spain)minorChannel Partner/ Reseller/ DistributorPilot program in Spain testing DIAGNOS AI-powered eye screening technology with European optical retailer for potential broader deployment.
  • Cielo Vista Eye Clinic (Mexico)coreChannel Partner/ Reseller/ Distributor3-year contract with Mexican eye clinic for deployment of AI-powered retinal analysis services, representing established presence in Latin American market.
  • Chaparral Medical Group (California)coreChannel Partner/ Reseller/ Distributor3-year contract with California medical group for AI screening services deployment, representing U.S. market presence in healthcare screening.
  • Juarez Health Medical Tourism ClustercoreChannel Partner/ Reseller/ DistributorMulti-year contract with medical tourism cluster for AI-assisted healthcare screening services targeting international patients.
  • Optina DiagnosticscoreStrategic or Co-development Partner3-year contract renewal with existing strategic partner for continued collaboration on AI-powered diagnostic solutions.
  • Colombia Telemedecine CentreminorChannel Partner/ Reseller/ DistributorService agreement with Colombian telemedicine organization for deployment of DIAGNOS screening technology in Latin America.
  • Magrabi HospitalcoreStrategic or Co-development PartnerOfficial opening of AI-assisted screening clinic at Magrabi Hospital, establishing presence in Middle East healthcare market.

Scale indicators9 records

Recent moves6 records

Expansion highlights7 records

Diagnos Inc. competitors and assessment

Company assessment

Direct peers

  • Eyenuk: Eyenuk's EyeArt AI system is an FDA-cleared autonomous diabetic retinopathy screening platform sold to primary care and optometry networks. Directly comparable to DIAGNOS' CARA in target use case (diabetic retinopathy screening) and customer base (eye care clinics, primary care).
  • AEYE Health: AEYE Health provides FDA-cleared AI-based retinal screening for diabetic retinopathy with a single-image-per-eye workflow. Direct peer to DIAGNOS in autonomous AI screening sold to primary care and optometry channels.
  • Digital Diagnostics (formerly IDx): Digital Diagnostics developed IDx-DR, the first FDA-cleared autonomous AI for diabetic retinopathy detection. Direct competitor to DIAGNOS in AI retinal screening for primary care and eye care settings, with similar clinical validation and regulatory positioning.
  • RetinAI Medical (Ikerian): RetinAI Discovery is an AI platform for retinal image analysis and ophthalmology data management used in clinical research and screening workflows. Comparable to DIAGNOS in retinal AI analytics and clinical/research deployments.

Broad incumbents

  • Optos (Nikon): Optos, owned by Nikon, provides ultra-widefield retinal imaging devices (optomap) used in diabetic retinopathy screening and ocular disease detection. Sells imaging hardware and integrated screening solutions across the same customer segments as DIAGNOS.
  • Topcon Healthcare: Topcon is a major ophthalmic imaging and healthcare technology company whose Harmony/Imagenet clinical data platforms integrate with AI screening. Broader portfolio than DIAGNOS but operates in the same retinal imaging and screening ecosystem.
  • Carl Zeiss Meditec (ZEISS Medical Technology): ZEISS Meditec is a major ophthalmic device and diagnostics company with CIRRUS OCT and integrated screening workflows. Broad incumbent in retinal imaging that DIAGNOS integrates with and competes against for clinical workflow budget.
  • Heidelberg Engineering: Heidelberg Engineering is a global leader in OCT, confocal microscopy, and retinal imaging hardware used in ophthalmology. Provides the imaging devices DIAGNOS often integrates with and competes indirectly via their own AI workflows (Heidelberg AppWay).

Emerging players

  • RetinaLyze System: RetinaLyze offers cloud-based AI screening for diabetic retinopathy and other retinal conditions, primarily serving European primary care and optometry. Overlaps with DIAGNOS in AI retinal screening use case, though at smaller commercial scale.
  • Verily (Alphabet): Verily (an Alphabet company) has developed AI-driven retinal screening for diabetic retinopathy and cardiovascular risk assessment. A platform-scale emerging player whose capabilities overlap directly with DIAGNOS' CARA and CARA STROKE roadmaps.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Diagnos Inc. social profiles

Digital presence

Diagnos Inc. compliance and trust

Trust signal

Compliance6 records

Diagnos Inc. financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Diagnos Inc. leadership team

Management profile

Number of profiles

Profiles13 records

Diagnos Inc. funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Diagnos Inc. M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Diagnos Inc.

What does Diagnos Inc. do?

DIAGNOS develops and commercializes AI-powered retinal image analysis software (centered on its CARA System) for the early detection of diabetic retinopathy and other ocular diseases. The platform combines proprietary deep learning algorithms trained on 500,000+ retinal images with a real-time cloud-based analysis infrastructure, deployed to hospitals, eye clinics, optical retailers, and medical tourism operators under multi-year licensing and subscription contracts.

Is Diagnos Inc. a public or private company?

Diagnos Inc. is a public company. It is classified as public and is currently operating.

When was Diagnos Inc. founded?

Diagnos Inc. was founded in 2008.

Where is Diagnos Inc. based?

Diagnos Inc. is headquartered in Brossard, Canada, in the North America region.

How does Diagnos Inc. make money?

Three revenue lines are on record. AI Medical Analysis Services are the primary driver. The others are technology Licensing and professional Services.

Who are Diagnos Inc.'s main competitors?

Direct peers on record are Eyenuk, AEYE Health, Digital Diagnostics (formerly IDx) and RetinAI Medical (Ikerian). Broad incumbents are Optos (Nikon), Topcon Healthcare, Carl Zeiss Meditec (ZEISS Medical Technology) and Heidelberg Engineering. Emerging players are RetinaLyze System and Verily (Alphabet).

Does Diagnos Inc. have an API?

No public API is recorded for Diagnos Inc..

What industry is Diagnos Inc. in?

Diagnos Inc.'s product category is AI Medical Imaging Software. Its primary akta.pro industry code is HDAAAEAH, Medical Imaging AI, with a secondary code of HLAHAJAB, Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography). Its NAICS code is 621320 and its SIC code is 3827.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
stockhouseSmall-cap Canadian healthcare firm expands AI-screening at home and abroadDiagnos Inc. expanded its AI-based CARA platform for retinal disease screening, gaining Health Canada and Saudi Arabia approvals. Over 60 optometrists in Canada use the system, and the company plans to roll out across all provinces. The stock closed at $0.35, up 2.94% year-over-year.Business InsiderDIAGNOS Successfully Completes ISO 13485 / MDSAP Audit and receives its certification to move forward with FDA and Health CanadaDIAGNOS Inc. announced completion of its ISO 13485 and MDSAP audit, receiving certification to proceed with FDA and Health Canada licensing. The certification covers its FLAIRE AI platform and CARA product, enabling global sales. The company is also seeking licenses for four additional retinal imaging modules.InvestorintelEyes on DIAGNOS as commercialization gains momentumDIAGNOS Inc. is commercializing its FLAIRE AI tele-ophthalmology platform, CARA, which has cleared from Health Canada, FDA, CE, COFEPRIS, and Saudi FDA. The company operates in 16 countries with 131 screening sites and 222,034 patients. Revenue is forecast to rise from C$270,000 in 2021 to C$800,000 in 2022 and C$7,920,000 in 2023.AiThorityDIAGNOS and the third largest optical retailer in Costa Rica Piloting CARA and its Telemedicine technologyDiagnos signed a contract with Costa Rica's third-largest optical chain, Óptica Central, to pilot its CARA telemedicine platform across the country. The AI-based system screens for diabetic retinopathy, a leading cause of blindness, with nearly 15% of Costa Rica's population over 20 having diabetes and less than 11% diagnosed.GlobeNewswireDundee Corporation Acquires Further Interest in Diagnos Inc.Dundee Corporation acquired 1,000,000 common shares of Diagnos Inc. through its subsidiary Dundee Resources, paying $0.06 per share. The purchase raised Dundee's undiluted stake to approximately 9.28% and partially diluted stake to 11.10%. Dundee intends to review the investment and may buy more or sell some shares.